Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons

David H. Dockrell, Gregory A. Poland, Thomas F. Smith, Mary F. Jones, Peter C. Wollan, Scott R. Strickland, Claire Pomeroy

Research output: Contribution to journalArticle

Abstract

Objective: Parvovirus B19 is an important cause of chronic anemia in human immunodeficiency virus (HIV)-positive patients. Extensive seroprevalence studies for parvovirus B19 in HIV-positive individuals have not been carried out in the United States. The authors compared the seroprevalence for parvovirus B19 among patients with asymptomatic HIV infection and healthy blood donors. Methods: The seroprevalence of IgG antibodies to VP-1, a parvovirus B19 structural protein, was determined using an indirect enzyme immunoassay (EIA) and a Western blot assay in 72 HIV- positive adults without prior opportunistic infection or acquired immunodeficiency syndrome (AIDS)-related malignancy and results were compared to those of 134 healthy blood donors. Results: There was a significantly higher seroprevalence for parvovirus B19 in HIV-positive subjects (57/72, 79%) than in the controls (58/134, 43%) (P < 0.001). Analysis by indirect EIA of the HIV-positive subjects 1 year later showed no significant change in seropositivity (48/70, 69%). For HIV-positive subjects, B19 seropositivity was not significantly related to age, sex, or CD4 count, but the parvovirus index did correlate with the total IgG level at both time points (P = 0.014 at the first estimation and P = 0.045 1 year later). Western blot analysis of IgG antibody to the VP-1 protein showed that 49 of 71 (69%) of the HIV- positive subjects were positive at the beginning of the study, and 50 of 71 (70%) were positive 1 year later. Conclusions: These results suggest an increased seropositivity to parvovirus B19 among HIV-positive individuals compared to healthy controls.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalInternational Journal of Infectious Diseases
Volume2
Issue number2
DOIs
StatePublished - 1997

Fingerprint

Parvovirus
Seroepidemiologic Studies
HIV
Antibodies
Viral Structural Proteins
Immunoglobulin G
Blood Donors
Immunoenzyme Techniques
Western Blotting
Opportunistic Infections
Virus Diseases
CD4 Lymphocyte Count
Anemia
Acquired Immunodeficiency Syndrome
Proteins

Keywords

  • Asymptomatic HIV-positive
  • B19 antibody
  • Parvovirus seroprevalence

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Dockrell, D. H., Poland, G. A., Smith, T. F., Jones, M. F., Wollan, P. C., Strickland, S. R., & Pomeroy, C. (1997). Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons. International Journal of Infectious Diseases, 2(2), 99-104. https://doi.org/10.1016/S1201-9712(97)90090-4

Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons. / Dockrell, David H.; Poland, Gregory A.; Smith, Thomas F.; Jones, Mary F.; Wollan, Peter C.; Strickland, Scott R.; Pomeroy, Claire.

In: International Journal of Infectious Diseases, Vol. 2, No. 2, 1997, p. 99-104.

Research output: Contribution to journalArticle

Dockrell, DH, Poland, GA, Smith, TF, Jones, MF, Wollan, PC, Strickland, SR & Pomeroy, C 1997, 'Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons', International Journal of Infectious Diseases, vol. 2, no. 2, pp. 99-104. https://doi.org/10.1016/S1201-9712(97)90090-4
Dockrell, David H. ; Poland, Gregory A. ; Smith, Thomas F. ; Jones, Mary F. ; Wollan, Peter C. ; Strickland, Scott R. ; Pomeroy, Claire. / Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons. In: International Journal of Infectious Diseases. 1997 ; Vol. 2, No. 2. pp. 99-104.
@article{456208c6c1154027807efe3d4664b53c,
title = "Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons",
abstract = "Objective: Parvovirus B19 is an important cause of chronic anemia in human immunodeficiency virus (HIV)-positive patients. Extensive seroprevalence studies for parvovirus B19 in HIV-positive individuals have not been carried out in the United States. The authors compared the seroprevalence for parvovirus B19 among patients with asymptomatic HIV infection and healthy blood donors. Methods: The seroprevalence of IgG antibodies to VP-1, a parvovirus B19 structural protein, was determined using an indirect enzyme immunoassay (EIA) and a Western blot assay in 72 HIV- positive adults without prior opportunistic infection or acquired immunodeficiency syndrome (AIDS)-related malignancy and results were compared to those of 134 healthy blood donors. Results: There was a significantly higher seroprevalence for parvovirus B19 in HIV-positive subjects (57/72, 79{\%}) than in the controls (58/134, 43{\%}) (P < 0.001). Analysis by indirect EIA of the HIV-positive subjects 1 year later showed no significant change in seropositivity (48/70, 69{\%}). For HIV-positive subjects, B19 seropositivity was not significantly related to age, sex, or CD4 count, but the parvovirus index did correlate with the total IgG level at both time points (P = 0.014 at the first estimation and P = 0.045 1 year later). Western blot analysis of IgG antibody to the VP-1 protein showed that 49 of 71 (69{\%}) of the HIV- positive subjects were positive at the beginning of the study, and 50 of 71 (70{\%}) were positive 1 year later. Conclusions: These results suggest an increased seropositivity to parvovirus B19 among HIV-positive individuals compared to healthy controls.",
keywords = "Asymptomatic HIV-positive, B19 antibody, Parvovirus seroprevalence",
author = "Dockrell, {David H.} and Poland, {Gregory A.} and Smith, {Thomas F.} and Jones, {Mary F.} and Wollan, {Peter C.} and Strickland, {Scott R.} and Claire Pomeroy",
year = "1997",
doi = "10.1016/S1201-9712(97)90090-4",
language = "English (US)",
volume = "2",
pages = "99--104",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Seroprevalence of parvovirus B19 antibody in HIV-positive asymptomatic persons

AU - Dockrell, David H.

AU - Poland, Gregory A.

AU - Smith, Thomas F.

AU - Jones, Mary F.

AU - Wollan, Peter C.

AU - Strickland, Scott R.

AU - Pomeroy, Claire

PY - 1997

Y1 - 1997

N2 - Objective: Parvovirus B19 is an important cause of chronic anemia in human immunodeficiency virus (HIV)-positive patients. Extensive seroprevalence studies for parvovirus B19 in HIV-positive individuals have not been carried out in the United States. The authors compared the seroprevalence for parvovirus B19 among patients with asymptomatic HIV infection and healthy blood donors. Methods: The seroprevalence of IgG antibodies to VP-1, a parvovirus B19 structural protein, was determined using an indirect enzyme immunoassay (EIA) and a Western blot assay in 72 HIV- positive adults without prior opportunistic infection or acquired immunodeficiency syndrome (AIDS)-related malignancy and results were compared to those of 134 healthy blood donors. Results: There was a significantly higher seroprevalence for parvovirus B19 in HIV-positive subjects (57/72, 79%) than in the controls (58/134, 43%) (P < 0.001). Analysis by indirect EIA of the HIV-positive subjects 1 year later showed no significant change in seropositivity (48/70, 69%). For HIV-positive subjects, B19 seropositivity was not significantly related to age, sex, or CD4 count, but the parvovirus index did correlate with the total IgG level at both time points (P = 0.014 at the first estimation and P = 0.045 1 year later). Western blot analysis of IgG antibody to the VP-1 protein showed that 49 of 71 (69%) of the HIV- positive subjects were positive at the beginning of the study, and 50 of 71 (70%) were positive 1 year later. Conclusions: These results suggest an increased seropositivity to parvovirus B19 among HIV-positive individuals compared to healthy controls.

AB - Objective: Parvovirus B19 is an important cause of chronic anemia in human immunodeficiency virus (HIV)-positive patients. Extensive seroprevalence studies for parvovirus B19 in HIV-positive individuals have not been carried out in the United States. The authors compared the seroprevalence for parvovirus B19 among patients with asymptomatic HIV infection and healthy blood donors. Methods: The seroprevalence of IgG antibodies to VP-1, a parvovirus B19 structural protein, was determined using an indirect enzyme immunoassay (EIA) and a Western blot assay in 72 HIV- positive adults without prior opportunistic infection or acquired immunodeficiency syndrome (AIDS)-related malignancy and results were compared to those of 134 healthy blood donors. Results: There was a significantly higher seroprevalence for parvovirus B19 in HIV-positive subjects (57/72, 79%) than in the controls (58/134, 43%) (P < 0.001). Analysis by indirect EIA of the HIV-positive subjects 1 year later showed no significant change in seropositivity (48/70, 69%). For HIV-positive subjects, B19 seropositivity was not significantly related to age, sex, or CD4 count, but the parvovirus index did correlate with the total IgG level at both time points (P = 0.014 at the first estimation and P = 0.045 1 year later). Western blot analysis of IgG antibody to the VP-1 protein showed that 49 of 71 (69%) of the HIV- positive subjects were positive at the beginning of the study, and 50 of 71 (70%) were positive 1 year later. Conclusions: These results suggest an increased seropositivity to parvovirus B19 among HIV-positive individuals compared to healthy controls.

KW - Asymptomatic HIV-positive

KW - B19 antibody

KW - Parvovirus seroprevalence

UR - http://www.scopus.com/inward/record.url?scp=0031415452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031415452&partnerID=8YFLogxK

U2 - 10.1016/S1201-9712(97)90090-4

DO - 10.1016/S1201-9712(97)90090-4

M3 - Article

VL - 2

SP - 99

EP - 104

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

IS - 2

ER -